Systemic sclerosis (scleroderma, SSc) — overview & organ-based management (limited/diffuse cutaneous; distinct from renal crisis entry)
Bedside summary
Multisystem autoimmune connective tissue disease characterised by vasculopathy, immune activation and progressive fibrosis of skin and internal organs. Two main subsets: limited cutaneous SSc (skin distal to elbows/knees + face; CREST — Calcinosis, Raynaud, oEsophageal dysmotility, Sclerodactyly, Telangiectasia; anticentromere antibody; late pulmonary hypertension) and diffuse cutaneous SSc (proximal skin involvement; anti-Scl-70/RNA polymerase III; early ILD and renal crisis risk). Leading causes of death are pulmonary (ILD and pulmonary arterial hypertension). Management is organ-specific — there is no single disease-modifying cure. (Scleroderma renal crisis has its own dedicated entry.)
Red flags
- New hypertension + rising creatinine +/- headache/visual change — SCLERODERMA RENAL CRISIS (start ACE inhibitor now, do not delay)
- Rapidly progressive breathlessness/hypoxia — ILD progression or PAH
- Syncope/chest pain/right heart failure signs — pulmonary arterial hypertension
- Black/necrotic fingertip, critical digital ischaemia — needs iloprost/vasodilators, risk of gangrene
- High-dose corticosteroid exposure in diffuse SSc — precipitates renal crisis
Assessment
Differential diagnosis
- Primary Raynaud phenomenon (no organ involvement, normal nailfold capillaries, negative serology)
- Mixed connective tissue disease / overlap (anti-U1-RNP positive)
- Eosinophilic fasciitis (spares hands/face, peau d'orange, eosinophilia, Raynaud absent)
- Scleromyxoedema, nephrogenic systemic fibrosis, scleroedema (diabetes)
- Chronic GVHD; morphoea (localised scleroderma, no systemic/Raynaud)
Investigations
- ANA + SSc-specific antibodies: anticentromere (limited), anti-Scl-70/topoisomerase (diffuse+ILD), anti-RNA polymerase III (diffuse+renal crisis/malignancy link)
- Nailfold capillaroscopy (dilated loops, dropout = SSc pattern)
- High-resolution CT chest + pulmonary function tests (FVC, DLCO) for ILD screen
- Transthoracic echocardiography annually (estimate PASP) + NT-proBNP — screen for pulmonary arterial hypertension; right heart catheter to confirm
- BP + U&E monitoring (renal crisis surveillance, especially early diffuse/anti-RNA pol III)
- ECG/Holter (conduction disease, myocardial involvement); barium swallow/manometry if dysphagia
- FBC, blood film (microangiopathic haemolysis in renal crisis)
Management
- Classify subset (limited vs diffuse) and define dominant organ involvement — this drives therapy
- Raynaud/digital ischaemia: cold avoidance, calcium-channel blocker first-line; PDE5 inhibitor and/or IV iloprost for digital ulcers; bosentan to prevent new ulcers
- Skin fibrosis (progressive diffuse): methotrexate, mycophenolate mofetil, and/or rituximab; tocilizumab an option
- ILD: mycophenolate mofetil or cyclophosphamide; nintedanib (antifibrotic) alone or with MMF; tocilizumab/rituximab in selected; consider lung transplant referral
- Pulmonary arterial hypertension: refer PH centre — combination PDE5 inhibitor + endothelin receptor antagonist first-line; IV prostacyclin (epoprostenol) for advanced
- GI: PPI for reflux/oesophagitis, prokinetics for dysmotility, rotating antibiotics for small-bowel bacterial overgrowth; nutrition support
- BLOOD PRESSURE VIGILANCE: new hypertension + AKI = scleroderma renal crisis — start ACE inhibitor immediately (see renal crisis entry); AVOID high-dose steroids (>15 mg/day prednisolone) which precipitate it
- Supportive: avoid cold/beta-blockers, treat calcinosis, physiotherapy, vaccination, severe refractory diffuse disease may be considered for autologous stem-cell transplant
Drugs & doses
Disposition
Complications & pitfalls
- Interstitial lung disease and pulmonary arterial hypertension (leading causes of death)
- Scleroderma renal crisis
- Digital ulcers, gangrene, autoamputation; calcinosis
- GI: reflux, dysmotility, bacterial overgrowth, gastric antral vascular ectasia ('watermelon stomach'), malnutrition
- Myocardial fibrosis, arrhythmia, conduction block; secondary Sjogren
Exam pearls
- AVOID glucocorticoid doses >15 mg/day prednisolone in SSc — a major precipitant of scleroderma renal crisis (worst in diffuse / anti-RNA polymerase III).
- EULAR 2023 (updated) added mycophenolate, nintedanib, rituximab and tocilizumab as organ-directed options for skin/lung.
- Anti-RNA polymerase III = highest renal crisis + malignancy association; anti-Scl-70 = ILD; anticentromere = limited disease/late PAH.
- Screen every SSc patient annually with echo + PFTs for PAH and ILD — presymptomatic detection improves outcome.
- ACE inhibitor is life-saving in renal crisis and must be continued despite rising creatinine — the opposite of usual AKI management.
- Nailfold capillaroscopy + SSc antibodies distinguish early SSc from primary Raynaud.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.